ClinicalTrials.gg
CompletedNCT00895583Updated Sep 18, 2014Results posted

Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients

A Phase 4 interventional study of Tacrolimus and Sirolimus in Graft Rejection, Kidney Transplant and Renal Allograft Recipients, sponsored by Pfizer. Completed at 44 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-18.

Sponsored by Pfizer · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will look at the effect on long-term kidney function using tacrolimus right after a transplant and then switching to sirolimus at 3 to 5 months after the transplant.

02

Conditions studied

  • Graft Rejection
  • Kidney Transplant
  • Renal Allograft Recipients
  • Renal Transplant

Keywords

  • renal transplant
  • immunosuppression
  • sirolimus/rapamune
  • planned transition
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

At Screening:

  • Male or female subjects aged 18 years or older.
  • Recipients who are 14 days prior to transplantation up through 14 days after transplantation.
  • Recipients of a primary, living- or deceased-donor renal allograft.
  • All female and male subjects who are biologically capable of having children must agree and commit to the use of a reliable method of for the duration of the study and for 3 months after the last dose of test article. A subject is biologically capable of having children even if he or she is using contraceptives or if his or her sexual partner is sterile or using contraceptives.

At Randomization:

  • Ninety (90) to 150 days post-transplantation.
  • Treatment with tacrolimus and an inosine monophosphate dehydrogenase (IMPDH) inhibitor initiated less than or equal to 30 days of transplantation and has remained on both for the 30 days prior to randomization.

Exclusion criteria

Exclusion Criteria:

At Screening:

  • Recipients of multiple organ transplants (i.e., any prior or concurrent transplantation of any organs including prior renal transplant. )
  • Recipients of adult or pediatric en bloc kidney transplants.
  • Recipients who required or will require desensitization protocols.
  • Known history of focal segmental glomerulosclerosis (FSGS) or membranoproliferative glomerulonephritis (MPGN).
  • Evidence of active systemic or localized major infection, as determined by the investigator.
  • Received any drugs or devices less than or equal to 30 days prior to transplantation.
  • Known or suspected allergy to sirolimus (SRL), tacrolimus (TAC), inosine-monophosphate dehydrogenase (IMPDH) inhibitor, macrolide antibiotics, iothalamate, iodine, iodine-containing products, including contrast media other compounds related to these products/classes of medication, or shellfish.
  • History of less than or equal to 3 years of screening (except for adequately treated basal cell or squamous cell carcinoma of the skin).
  • Recipients who are known to be (HIV) positive.
  • Women who are biologically capable of having children with a positive urine or serum pregnancy test at screening.
  • Breastfeeding women.

At Randomization:

  • Any major illness/condition that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of the study, or could preclude the evaluation of the subject's response.
  • Planned treatment with therapies other than those described in the protocol.
  • Subjects who underwent withdrawal or avoidance and did not receive antibody induction at the time of transplantation with anti-thymocyte globulin (rabbit) (rATG) (Thymoglobulin®), anti-thymocyte globulin (equine) (Atgam®), or alemtuzumab (Campath®).
  • Subjects who have had corticosteroid (CS) discontinued less than or equal to 30 days before randomization.
  • Calculated (GFR) less than 40 mL/min/1.73m2 using the simplified Modification of Diet in Renal Disease (MDRD) formula less than or equal to 2 weeks prior to randomization.
  • Spot urine protein to creatinine ratio (UPr/Cr) greater than or equal to 0.5 less than or equal to 2 weeks prior to randomization.
  • Banff (2007) grade 2 or higher acute T-cell-mediated or any acute antibody-mediated rejection at any time post-transplantation.
  • Any acute rejection (-confirmed or presumed) less than or equal to 30 days before randomization.
  • More than 1 episode of acute rejection (biopsy-confirmed or presumed).
  • Known Banff (2007) interstitial fibrosis and tubular atrophy (IF/TA) greater than or equal to grade 2 or recurrent/de novo glomerular disease.
  • Major surgery less than or equal to 2 weeks prior to randomization.
  • Active post-operative complication, e.g. infection, delayed wound healing.
  • Total white blood cell count less than 2,000/mm3 or (ANC) less than 1000 or count less than 100,000/mm3 less than or equal to 2 weeks prior to randomization.
  • Fasting triglycerides greater than 400 mg/dL (greater than 4.5 mmol/L) or fasting total cholesterol greater than 300 mg/dL (greater than 7.8 mmol/L) less than or equal to 2 weeks prior to randomization regardless of whether or not on lipid-lowering therapy.
  • Women who are biologically capable of having children with a positive urine or serum pregnancy test at randomization.
  • Breastfeeding women.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
254 participants (actual)

Study arms

  • Experimental
    Group I - Planned transition to sirolimus from tacrolimus

    Drug: Tacrolimus · Drug: Sirolimus

  • Active comparator
    Group II - Continuation of tacrolimus

    Drug: Tacrolimus

Interventions

  • During the screening phase, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is from transplantation until randomization (from 90 to 150 days).

    Also known as: Prograf, Adagraf

  • Following randomization, sirolimus is provided by the Sponsor in 1 and 2 mg oral tablets. Sirolimus is dosed once daily to achieve a target trough level of 7 to 15 ng/mL in the 1st year post-transplant and 5 - 15 ng/mL in the 2nd year post-transplant. Duration of treatment is from randomization through 2 years post-transplant (19 to 21 months).

    Also known as: Rapamune

  • During the study, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is 2 years post-transplant.

    Also known as: Prograf, adagraf

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Improvement of Greater Than or Equal to [≥]5 Milliliters Per Minute Per 1.73 Square Meters (mL/Min/m^2) in Calculated Glomerular Filtration Rate (GFR) at 24 Months Post-Transplantation (On-Therapy Analysis)

    GFR was calculated using the Modified Diet in Renal Disease (MDRD) equation using either serum creatinine traceable to isotope dilution mass spectrometry (IDMS) or serum creatinine not traceable to IDMS.

    Time frame: Baseline, Month 24

Secondary outcomes

  1. Percentage of Participants With Improvement of ≥5 mL/Min/m^2 in Calculated GFR at 12 Months Post-Transplantation (On-Therapy Analysis)

    GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS.

    Time frame: Baseline, Month 12

  2. Percentage of Participants With Improvement of ≥5 mL/Min/m^2 in Calculated GFR at 12 and 24 Months Post-Transplantation (Intent-to-Treat [ITT] Analysis)

    GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS.

    Time frame: Baseline, Months 12 and 24

  3. Percentage of Participants With Improvement of ≥7.5 mL/Min/m^2 in Calculated GFR at 12 and 24 Months Post-Transplantation

    GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS.

    Time frame: Baseline, Months 12 and 24

  4. Percentage of Participants With Improvement of ≥10 mL/Min/m^2 in Calculated GFR at 12 and 24 Months Post-Transplantation

    GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS.

    Time frame: Baseline, Months 12 and 24

  5. Calculated GFR Using MDRD (On-Therapy Analysis)

    GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS. Baseline was defined as the last nonmissing assessment before or on the date of the first dose of test article.

    Time frame: Baseline, Months 6, 12, 18, and 24

  6. Change From Randomization in Calculated GFR Using MDRD (On-Therapy Analysis)

    GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS. Baseline was defined as the last nonmissing assessment before or on the date of the first dose of test article.

    Time frame: Baseline, Months 6, 12, 18, and 24

  7. Slope of Calculated GFR (MDRD) From Randomization to 24 Months Post-Transplantation (On-Therapy Analysis)

    GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS. Timepoints were calculated as study days, relative to the time of randomization of study medication. All available on-therapy values were included. Observed data were multiplied by a scale factor of 365, expressing the slope as an annual change.

    Time frame: Baseline, Month 24

  8. Serum Creatinine (On-Therapy Analysis)

    Serum creatinine was measured in micromillimoles per liter (mcmol/L). Baseline was defined as the last nonmissing assessment before or on the date of the first dose of test article.

    Time frame: Baseline, Months 6, 12, 18, and 24

  9. Change From Randomization in Serum Creatinine (On-Therapy Analysis)

    Serum creatinine was measured in mcmol/L. Baseline was defined as the last assessment prior to first administration of study drug.

    Time frame: Baseline, Months 6, 12, 18, and 24

  10. Percentage of Participants With Biopsy-Confirmed Acute Rejection (BCAR), Graft Loss, or Death From Randomization to 24 Months Post-Transplantation

    Biopsy-confirmed acute rejection was defined according to updated Banff criteria (2007) for renal allograft rejection. Graft loss was defined as physical loss (nephrectomy or retransplantation), functional loss (requiring dialysis for greater than or equal to \[≥\]56 days with no return of graft function), or death.

    Time frame: Post-randomization to Month 24 post-transplantation

  11. Percentage of Participants With Graft Loss (Including Death) at 12 and 24 Months Post-Randomization

    Graft loss was defined as physical loss (nephrectomy or retransplantation), functional loss (requiring dialysis for ≥56 days with no return of graft function), or death.

    Time frame: Post-randomization to Months 12 and 24 Post-Transplantation

  12. Percentage of Participants With BCAR Post-Randomization to 6, 12, 18, and 24 Months Post-Transplantation

    BCAR was defined according to updated Banff criteria (2007) for renal allograft rejection.

    Time frame: Post-Randomization to 6, 12, 18, and 24 months Post-Transplantation

  13. Percentage of Participants With First On-Therapy BCAR From Transplantation Occurring at 12 and 24 Months

    Defined as the first BCAR occurring during the On-Therapy period based on the ITT population. Time to first BCAR was the days from transplantation to the date of BCAR.

    Time frame: Months 12 and 24

  14. Number of Participants With BCAR by Severity of First BCAR and Time of Onset From Post-Randomization to 6, 12, 18, and 24 Months Post-Transplant

    BCAR was categorized as antibody-mediated (AM) or T-cell. AM BCAR severity was graded as Grade I (mild), Grade II (moderate), and Grade III (severe). T-cell BCAR severity was graded as 'Grade Ia, Ib (mild), Grade IIa, IIb (moderate), and Grade III (severe). If a participant had both T-cell BCAR and antibody-mediated BCAR on the first rejection, the participant was counted in each category.

    Time frame: Months 6, 12, 18, and 24

  15. Percentage of Participants With Antibody Use in Treatment of Acute Rejection

    Number of participants who experienced an adverse event (AE) of rejection was used as the denominator in the determination of percentage of participants with antibody use in treatment of acute rejection.

    Time frame: On Therapy Period (up to 21 months post-randomization) and Off-Therapy Period (up to 24 months post-transplantation)

  16. Percentage of Participants With Anemia, Thrombocytopenia, or Leukopenia

    Anemia was defined as hemoglobin less than or equal to (≤)10 grams per deciliter (g/dL); leukopenia was defined as white blood cell (WBC) count ≤2000 per cubic millimeters (/mm\^3); and thrombocytopenia was defined as platelets ≤100,000/mm\^3. Baseline was defined as the last nonmissing assessment before or on the date of the first dose of test article.

    Time frame: Baseline, Months 12 and 24

  17. Change From Baseline (Pre-Randomization) to 12 and 24 Months Post-Transplantation in Fasting Lipid Parameters (Millimoles Per Liter [mmol/L])

    Parameters assessed included total cholesterol (TC), triglycerides, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C); collected when participant was in a fasting state.

    Time frame: Baseline, Months 12 and 24

  18. Percentage of Participants Requiring Anti-Hypertensive Medication, Diabetes Agents, Lipid-Lowering Agents, or Erythropoiesis Stimuating Agents (ESAs)

    Time frame: Baseline, Months 12 and 24

  19. Spot and 24 Hour Urine Protein to Creatinine Ratio (UPr/Cr)

    Baseline was defined as the last nonmissing assessment before or on the date of the first dose of test article.

    Time frame: Baseline and Months 12 and 24

  20. Percentage of Participants With Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor Block (ARB) Use

    Included ACEI or ARB use prior to randomization, during the on-therapy period (up to 19 to 21 months post randomization) and the off-therapy period (up to 24 months post-transplantation).

    Time frame: Pre-randomization, On-Therapy Period (up to 21 months post-randomization), and Off-Therapy Period (up to 24 months post-transplantation)

  21. Percentage of Participants With Stomatitis

    Includes adverse events based on categorization by the investigator as stomatitis, regardless of the event preferred term in Medical Dictionary for Regulatory Activities (MedDRA)

    Time frame: From randomization up to 24 months after transplantation (On-Therapy)

  22. Percentage of Participants Requiring Treatment for Stomatitis by Treatment Type

    Included treatments (analgesics, dental paste, topical antifungal, topical steroids, or other) prior to randomization, during the on-therapy period (up to 19 to 21 months post-randomization) and the off-therapy period (up to 24 months post-transplantation).

    Time frame: On-Therapy Period (up to 21 months post-randomization) and Off-Therapy Period (up to 24 months post-transplantation)

  23. Change From Pre-Randomization to 12 Months Post-Transplantation in Hemoglobin A1C (Liter Per Liter [L/L])

    Ratio of hemoglobin A1c to normal hemoglobin.

    Time frame: Baseline, Month 12

  24. Change From Pre-Randomization to 12 Months Post-Transplantation in Fasting Glucose (mmol/L)

    Time frame: Baseline, Month 12

  25. Change From Pre-Randomization to 12 Months Post-Transplantation in Fasting Insulin (Picomoles Per Liter [Pmol/L])

    Time frame: Baseline, Month 12

  26. Change From Pre-Randomization to 12 Months Post-Transplantation in Weight (Kilograms [kg])

    Time frame: Baseline, Month 12

  27. Change From Pre-Randomization to 12 Months Post-Transplantation in Waist Circumference(Centimeters [cm])

    Time frame: Baseline, Month 12

  28. Change From Pre-Randomization to 12 Months Post-Transplantation in Homeostasis Model Assessment Insulin Resistance (HOMA-IR; Fasting)

    The HOMA-IR measures insulin resistance based on fasting glucose and insulin measurements: HOMA-IR = fasting plasma glucose (mmol/L) multiplied by (\*) fasting plasma insulin in microunits per liter (µU/L) divided by (/) 22.5. Participants taking insulin within 12 hours were excluded from the analysis.

    Time frame: Baseline, Month 12

  29. Change From Pre-Randomization to 12 Months Post-Transplantation in HOMA-Beta Cell (HOMA-B; Fasting)

    The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) as a percentage of a normal reference population. HOMA-B = 20 \* insulin (µU/L) / fasting plasma glucose (mmol/L) minus (-) 3.5 Participants taking insulin within 12 hours were excluded from the analysis.

    Time frame: Baseline, Month 12

  30. Change From Pre-Randomization to 12 Months Post-Transplantation in Body Mass Index (BMI; in Kilograms Per Square Meter [kg/m^2])

    BMI = Weight (kg)/(Height\*Height) (square meters \[m\^2\]).

    Time frame: Baseline, Month 12

  31. Percentage of Participants With New-Onset Diabetes

    Participants were considered as having new onset diabetes during the On-therapy period if any of the below events emerged from baseline to Month 24: 1) at least 30 days continuous, or at least 25 days non-stop (without gap) use of any diabetic treatment after randomization; 2) a fasting glucose greater than or equal to (≥)126 milligrams per deciliter (mg/dL) after randomization; or 3) a non-fasting glucose ≥200 mg/dL after randomization, were included in the new-onset diabetes population. Events at Months 12 or 24 occurred from baseline to On-therapy Month 12 and from On-therapy Months 12 to 24, respectively.

    Time frame: From Baseline to On-Therapy Month 12, from Baseline to On-Therapy Month 24, and from On-Therapy Month 12 up to On-Therapy Month 24

  32. Percentage of Participants With New-Onset Diabetes Receiving Treatment for Diabetes (Insulin and Non-Insulin)

    Participants were considered as having new onset diabetes during the On-therapy period if any of the below events emerged between baseline and Month 12 or Month 24: 1) at least 30 days continuous, or at least 25 days non-stop (without gap) use of any diabetic treatment after randomization; 2) a fasting glucose ≥126 mg/dL after randomization; or 3) a non-fasting glucose ≥200 mg/dL after randomization.

    Time frame: 12 Months and 24 Months

  33. Percentage of Participants With Infection

    Includes adverse events based on categorization by the investigator as 'infection', regardless of the event preferred term in MedDRA.

    Time frame: From randomization up to 24 months after transplantation (On-Therapy)

  34. Percentage of Participants With Cytomegalovirus (CMV) Infection

    Includes adverse event terms reported by the investigator to be attributed to the organism 'cytomegalovirus', regardless of the preferred term in MedDRA.

    Time frame: From randomization up to 24 months after transplantation (On-Therapy)

  35. Percentage of Participants With Polyomavirus Infection

    Includes adverse event terms reported by the investigator to be attributed to the organism 'polyomavirus', regardless of the preferred term in MedDRA.

    Time frame: From randomization up to 24 months after transplantation (On-Therapy)

  36. Percentage of Participants With Malignancy

    Includes any adverse events based on categorization by the investigator as 'malignancy', regardless of the event preferred term in MedDRA.

    Time frame: From randomization up to 24 months after transplantation (On-Therapy)

07

Results

Posted Sep 18, 2014

Participant flow

Participant flow — Overall Study
MilestoneSirolimusTacrolimus
Started131123
Completed87111
Not completed4412
Withdrew: Adverse event284
Withdrew: Death21
Withdrew: Physician decision31
Withdrew: Lost to follow-up13
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject42
Withdrew: Lack of efficacy50
Withdrew: Other01

Outcome measures

PrimaryPercentage of Participants With Improvement of Greater Than or Equal to [≥]5 Milliliters Per Minute Per 1.73 Square Meters (mL/Min/m^2) in Calculated Glomerular Filtration Rate (GFR) at 24 Months Post-Transplantation (On-Therapy Analysis)

GFR was calculated using the Modified Diet in Renal Disease (MDRD) equation using either serum creatinine traceable to isotope dilution mass spectrometry (IDMS) or serum creatinine not traceable to IDMS.

Time frame:
Baseline, Month 24
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement of Greater Than or Equal to [≥]5 Milliliters Per Minute Per 1.73 Square Meters (mL/Min/m^2) in Calculated Glomerular Filtration Rate (GFR) at 24 Months Post-Transplantation (On-Therapy Analysis)
percentage of participantsSirolimusTacrolimus
Percentage of Participants With Improvement of Greater Than or Equal to [≥]5 Milliliters Per Minute Per 1.73 Square Meters (mL/Min/m^2) in Calculated Glomerular Filtration Rate (GFR) at 24 Months Post-Transplantation (On-Therapy Analysis)33.742.2
Statistical analysis
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.239 (Two-sided alpha equals (=) 0.05.) · Odds ratio (or): 0.7 · 95% CI 0.4 to 1.3
SecondaryPercentage of Participants With Improvement of ≥5 mL/Min/m^2 in Calculated GFR at 12 Months Post-Transplantation (On-Therapy Analysis)

GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS.

Time frame:
Baseline, Month 12
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement of ≥5 mL/Min/m^2 in Calculated GFR at 12 Months Post-Transplantation (On-Therapy Analysis)
percentage of participantsSirolimusTacrolimus
Percentage of Participants With Improvement of ≥5 mL/Min/m^2 in Calculated GFR at 12 Months Post-Transplantation (On-Therapy Analysis)39.444.8
Statistical analysis
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.422 (Alpha was unadjusted.) · Odds ratio (or): 0.8 · 95% CI 0.5 to 1.4
SecondaryPercentage of Participants With Improvement of ≥5 mL/Min/m^2 in Calculated GFR at 12 and 24 Months Post-Transplantation (Intent-to-Treat [ITT] Analysis)

GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS.

Time frame:
Baseline, Months 12 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement of ≥5 mL/Min/m^2 in Calculated GFR at 12 and 24 Months Post-Transplantation (Intent-to-Treat [ITT] Analysis)
percentage of participantsSirolimusTacrolimus
Month 1238.242.3
Month 2433.640.7
Statistical analysis
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.524 (Alpha was unadjusted.) · Odds ratio (or): 0.8 · 95% CI 0.5 to 1.4
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.298 (Alpha was unadjusted.) · Odds ratio (or): 0.7 · 95% CI 0.4 to 1.2
SecondaryPercentage of Participants With Improvement of ≥7.5 mL/Min/m^2 in Calculated GFR at 12 and 24 Months Post-Transplantation

GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS.

Time frame:
Baseline, Months 12 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement of ≥7.5 mL/Min/m^2 in Calculated GFR at 12 and 24 Months Post-Transplantation
percentage of participantsSirolimusTacrolimus
Month 1224.435.8
Month 2425.230.9
Statistical analysis
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.055 (Alpha was unadjusted.) · Odds ratio (or): 0.6 · 95% CI 0.3 to 1.0
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.330 (Alpha was unadjusted.) · Odds ratio (or): 0.8 · 95% CI 0.4 to 1.3
SecondaryPercentage of Participants With Improvement of ≥10 mL/Min/m^2 in Calculated GFR at 12 and 24 Months Post-Transplantation

GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS.

Time frame:
Baseline, Months 12 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement of ≥10 mL/Min/m^2 in Calculated GFR at 12 and 24 Months Post-Transplantation
percentage of participantsSirolimusTacrolimus
Month 1219.823.6
Month 2422.122.0
Statistical analysis
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.543 (Alpha was unadjusted.) · Odds ratio (or): 0.8 · 95% CI 0.4 to 1.5
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 1.000 (Alpha was unadjusted.) · Odds ratio (or): 1.0 · 95% CI 0.6 to 1.8
SecondaryCalculated GFR Using MDRD (On-Therapy Analysis)

GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS. Baseline was defined as the last nonmissing assessment before or on the date of the first dose of test article.

Time frame:
Baseline, Months 6, 12, 18, and 24
Reported as:
Mean · mL/min/1.73 m^2
Calculated GFR Using MDRD (On-Therapy Analysis)
mL/min/1.73 m^2SirolimusTacrolimus
Baseline (n=131,123)58.5 ± 14.357.4 ± 14.1
Month 6 (n=125,120)61.6 ± 14.957.6 ± 14.2
Month 12 (n=109,116)59.6 ± 16.461.3 ± 14.3
Month 18 (n=99,111)60.0 ± 15.059.8 ± 17.1
Month 24 (n=86,109)59.4 ± 18.058.4 ± 14.9
SecondaryChange From Randomization in Calculated GFR Using MDRD (On-Therapy Analysis)

GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS. Baseline was defined as the last nonmissing assessment before or on the date of the first dose of test article.

Time frame:
Baseline, Months 6, 12, 18, and 24
Reported as:
Mean · mL/min/1.73 m^2
Change From Randomization in Calculated GFR Using MDRD (On-Therapy Analysis)
mL/min/1.73 m^2SirolimusTacrolimus
Month 6 (n=125,120)2.7 ± 1.10.0 ± 0.8
Month 12 (n=109,116)1.5 ± 1.23.4 ± 1.1
Month 18 (n=99,111)2.2 ± 1.21.5 ± 1.3
Month 24 (n=86,109)1.2 ± 1.60.6 ± 1.3
Statistical analysis
  • Sirolimus vs Tacrolimus · ANCOVA · p = 0.019 (Alpha was unadjusted.) · Least squares (ls) mean difference: 3.0 · 95% CI 0.5 to 5.5Analysis of covariance (ANCOVA) with treatment as a factor and baseline GFR as a covariate.
  • Sirolimus vs Tacrolimus · ANCOVA · p = 0.215 (Alpha was unadjusted.) · Ls mean difference: -1.9 · 95% CI -4.8 to 1.1ANCOVA with treatment as a factor and baseline GFR as a covariate.
  • Sirolimus vs Tacrolimus · ANCOVA · p = 0.722 (Alpha was unadjusted.) · Ls mean difference: 0.6 · 95% CI -2.7 to 3.9ANCOVA with treatment as a factor and baseline GFR as a covariate.
  • Sirolimus vs Tacrolimus · ANCOVA · p = 0.710 (Alpha was unadjusted.) · Ls mean difference: 0.7 · 95% CI -3.0 to 4.4ANCOVA with treatment as a factor and baseline GFR as a covariate.
SecondarySlope of Calculated GFR (MDRD) From Randomization to 24 Months Post-Transplantation (On-Therapy Analysis)

GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS. Timepoints were calculated as study days, relative to the time of randomization of study medication. All available on-therapy values were included. Observed data were multiplied by a scale factor of 365, expressing the slope as an annual change.

Time frame:
Baseline, Month 24
Reported as:
Mean · mL/min/1.73 m^2 per year
Slope of Calculated GFR (MDRD) From Randomization to 24 Months Post-Transplantation (On-Therapy Analysis)
mL/min/1.73 m^2 per yearSirolimusTacrolimus
Slope of Calculated GFR (MDRD) From Randomization to 24 Months Post-Transplantation (On-Therapy Analysis)-0.9 (-2.7 to 0.8)0.9 (-0.7 to 2.5)
Statistical analysis
  • Sirolimus vs Tacrolimus · Random coefficient model · p = 0.131 · Slope difference (srl-tac): -1.8 · 95% CI -4.2 to 0.5Random coefficient model with GFR as the dependent variable and study day as the independent variable.
SecondarySerum Creatinine (On-Therapy Analysis)

Serum creatinine was measured in micromillimoles per liter (mcmol/L). Baseline was defined as the last nonmissing assessment before or on the date of the first dose of test article.

Time frame:
Baseline, Months 6, 12, 18, and 24
Reported as:
Mean · mcmol/L
Serum Creatinine (On-Therapy Analysis)
mcmol/LSirolimusTacrolimus
Baseline (n=131,123)118.3 ± 24.8117.7 ± 27.9
Month 6 (n=125,120)113.9 ± 27.6117.0 ± 28.2
Month 12 (n=109,116)119.6 ± 37.5109.4 ± 24.6
Month 18 (n=99,111)116.9 ± 33.1114.2 ± 30.4
Month 24 (n=86,109)122.9 ± 48.8117.5 ± 42.8
SecondaryChange From Randomization in Serum Creatinine (On-Therapy Analysis)

Serum creatinine was measured in mcmol/L. Baseline was defined as the last assessment prior to first administration of study drug.

Time frame:
Baseline, Months 6, 12, 18, and 24
Reported as:
Mean · mcmol/L
Change From Randomization in Serum Creatinine (On-Therapy Analysis)
mcmol/LSirolimusTacrolimus
Month 6 (n=125,120)-4.1 ± 2.0-0.0 ± 1.4
Month 12 (n=109,116)-0.3 ± 2.9-7.0 ± 1.9
Month 18 (n=99,111)-3.0 ± 2.5-1.9 ± 2.3
Month 24 (n=86,109)3.2 ± 4.60.5 ± 3.7
Statistical analysis
  • Sirolimus vs Tacrolimus · ANCOVA · p = 0.105 (Alpha was unadjusted.) · Ls mean difference: -3.9 · 95% CI -8.6 to 0.8ANCOVA with treatment as a factor and baseline serum creatinine as a covariate.
  • Sirolimus vs Tacrolimus · ANCOVA · p = 0.023 (Alpha was unadjusted.) · Ls mean difference: 7.7 · 95% CI 1.1 to 14.3ANCOVA with treatment as a factor and baseline serum creatinine as a covariate.
  • Sirolimus vs Tacrolimus · ANCOVA · p = 0.955 (Alpha was unadjusted.) · Ls mean difference: -0.2 · 95% CI -6.8 to 6.4ANCOVA with treatment as a factor and baseline serum creatinine as a covariate.
  • Sirolimus vs Tacrolimus · ANCOVA · p = 0.582 (Alpha was unadjusted.) · Ls mean difference: 3.2 · 95% CI -8.2 to 14.6ANCOVA with treatment as a factor and baseline serum creatinine as a covariate.
SecondaryPercentage of Participants With Biopsy-Confirmed Acute Rejection (BCAR), Graft Loss, or Death From Randomization to 24 Months Post-Transplantation

Biopsy-confirmed acute rejection was defined according to updated Banff criteria (2007) for renal allograft rejection. Graft loss was defined as physical loss (nephrectomy or retransplantation), functional loss (requiring dialysis for greater than or equal to \[≥\]56 days with no return of graft function), or death.

Time frame:
Post-randomization to Month 24 post-transplantation
Reported as:
Number · percentage of participants
Percentage of Participants With Biopsy-Confirmed Acute Rejection (BCAR), Graft Loss, or Death From Randomization to 24 Months Post-Transplantation
percentage of participantsSirolimusTacrolimus
Percentage of Participants With Biopsy-Confirmed Acute Rejection (BCAR), Graft Loss, or Death From Randomization to 24 Months Post-Transplantation11.52.4
Statistical analysis
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.006 (Alpha was unadjusted.)
SecondaryPercentage of Participants With Graft Loss (Including Death) at 12 and 24 Months Post-Randomization

Graft loss was defined as physical loss (nephrectomy or retransplantation), functional loss (requiring dialysis for ≥56 days with no return of graft function), or death.

Time frame:
Post-randomization to Months 12 and 24 Post-Transplantation
Reported as:
Number · percentage of participants
Percentage of Participants With Graft Loss (Including Death) at 12 and 24 Months Post-Randomization
percentage of participantsSirolimusTacrolimus
Month 120.80.0
Month 243.80.8
Statistical analysis
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 1.000 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.215 (Alpha was unadjusted.)
SecondaryPercentage of Participants With BCAR Post-Randomization to 6, 12, 18, and 24 Months Post-Transplantation

BCAR was defined according to updated Banff criteria (2007) for renal allograft rejection.

Time frame:
Post-Randomization to 6, 12, 18, and 24 months Post-Transplantation
Reported as:
Number · percentage of participants
Percentage of Participants With BCAR Post-Randomization to 6, 12, 18, and 24 Months Post-Transplantation
percentage of participantsSirolimusTacrolimus
Month 61.50.0
Month 125.30.8
Month 186.91.6
Month 248.41.6
Statistical analysis
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.499 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.067 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.061 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.020 (Alpha was unadjusted.)
SecondaryPercentage of Participants With First On-Therapy BCAR From Transplantation Occurring at 12 and 24 Months

Defined as the first BCAR occurring during the On-Therapy period based on the ITT population. Time to first BCAR was the days from transplantation to the date of BCAR.

Time frame:
Months 12 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With First On-Therapy BCAR From Transplantation Occurring at 12 and 24 Months
percentage of participantsSirolimusTacrolimus
Month 125.10.0
Month 249.30.9
SecondaryNumber of Participants With BCAR by Severity of First BCAR and Time of Onset From Post-Randomization to 6, 12, 18, and 24 Months Post-Transplant

BCAR was categorized as antibody-mediated (AM) or T-cell. AM BCAR severity was graded as Grade I (mild), Grade II (moderate), and Grade III (severe). T-cell BCAR severity was graded as 'Grade Ia, Ib (mild), Grade IIa, IIb (moderate), and Grade III (severe). If a participant had both T-cell BCAR and antibody-mediated BCAR on the first rejection, the participant was counted in each category.

Time frame:
Months 6, 12, 18, and 24
Reported as:
Number · participants
Number of Participants With BCAR by Severity of First BCAR and Time of Onset From Post-Randomization to 6, 12, 18, and 24 Months Post-Transplant
participantsSirolimusTacrolimus
Month 6, AM Grade I00
Month 6, AM Grade II00
Month 6, AM Grade III00
Month 6, T-cell Grade Ia, Ib20
Month 6, T-cell Grade IIa, IIb00
Month 6, T-cell Grade III00
Month 12, AM Grade I10
Month 12, AM Grade II00
Month 12, AM Grade III10
Month 12, T-cell Grade Ia, Ib50
Month 12, T-cell Grade IIa, IIb11
Month 12, T-cell Grade III00
Month 18, AM Grade I11
Month 18, AM Grade II00
Month 18, AM Grade III10
Month 18, T-cell Grade Ia, Ib71
Month 18, T-cell Grade IIa, IIb11
Month 18, T-cell Grade III00
Month 24, AM Grade I21
Month 24, AM Grade II10
Month 24, AM Grade III10
Month 24, T-cell Grade Ia, Ib81
Month 24, T-cell Grade IIa, IIb11
Month 24, T-cell Grade III00
SecondaryPercentage of Participants With Antibody Use in Treatment of Acute Rejection

Number of participants who experienced an adverse event (AE) of rejection was used as the denominator in the determination of percentage of participants with antibody use in treatment of acute rejection.

Time frame:
On Therapy Period (up to 21 months post-randomization) and Off-Therapy Period (up to 24 months post-transplantation)
Reported as:
Number · percentage of participants
Percentage of Participants With Antibody Use in Treatment of Acute Rejection
percentage of participantsSirolimusTacrolimus
On-therapy Period60.075.0
Off-therapy Period40.025.0
Statistical analysis
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 1.000 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 1.000 (Alpha was unadjusted.)
SecondaryPercentage of Participants With Anemia, Thrombocytopenia, or Leukopenia

Anemia was defined as hemoglobin less than or equal to (≤)10 grams per deciliter (g/dL); leukopenia was defined as white blood cell (WBC) count ≤2000 per cubic millimeters (/mm\^3); and thrombocytopenia was defined as platelets ≤100,000/mm\^3. Baseline was defined as the last nonmissing assessment before or on the date of the first dose of test article.

Time frame:
Baseline, Months 12 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Anemia, Thrombocytopenia, or Leukopenia
percentage of participantsSirolimusTacrolimus
Baseline (n=131,122)4.61.6
Month 12 (n=110,116)9.12.6
Month 24 (n=89,112)3.44.5
Statistical analysis
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.284 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.046 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 1.000 (Alpha was unadjusted.)
SecondaryChange From Baseline (Pre-Randomization) to 12 and 24 Months Post-Transplantation in Fasting Lipid Parameters (Millimoles Per Liter [mmol/L])

Parameters assessed included total cholesterol (TC), triglycerides, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C); collected when participant was in a fasting state.

Time frame:
Baseline, Months 12 and 24
Reported as:
Mean · mmol/L
Change From Baseline (Pre-Randomization) to 12 and 24 Months Post-Transplantation in Fasting Lipid Parameters (Millimoles Per Liter [mmol/L])
mmol/LSirolimusTacrolimus
TC, Change at Month 12 (n=96,107)0.66 ± 0.10-0.12 ± 0.07
TC, Change at Month 24 (n=74,88)0.51 ± 0.14-0.08 ± 0.09
HDL-C, Change at Month 12 (n=90,99)-0.00 ± 0.030.01 ± 0.02
HDL-C, Change at Month 24 (n=69,81)0.01 ± 0.040.01 ± 0.03
LDL-C, Change at Month 12 (n=87,98)0.43 ± 0.09-0.06 ± 0.07
LDL-C, Change at Month 24 (n=66,78)0.34 ± 0.13-0.06 ± 0.08
Triglycerides, Change at Month 12 (n=94,104)0.47 ± 0.11-0.18 ± 0.07
Triglycerides, Change at Month 24 (n=73,86)0.43 ± 0.100.07 ± 0.12
Statistical analysis
  • Sirolimus vs Tacrolimus · ANCOVA · p = <0.001 (Alpha was unadjusted.) · Difference in adjusted means: 0.81ANCOVA with treatment as a factor and baseline as a covariate.
  • Sirolimus vs Tacrolimus · ANCOVA · p = <0.001 (Alpha was unadjusted.) · Difference in adjusted mean: 0.61ANCOVA with treatment as a factor and baseline as a covariate.
  • Sirolimus vs Tacrolimus · ANCOVA · p = 0.824 (Alpha was unadjusted.) · Difference in adjusted means: -0.01ANCOVA with treatment as a factor and baseline as a covariate.
  • Sirolimus vs Tacrolimus · ANCOVA · p = 0.735 (Alpha was unadjusted.) · Difference in adjusted means: -0.02ANCOVA with treatment as a factor and baseline as a covariate.
  • Sirolimus vs Tacrolimus · ANCOVA · p = <0.001 (Alpha was unadjusted.) · Difference in adjusted means: 0.49ANCOVA with treatment as a factor and baseline as a covariate.
  • Sirolimus vs Tacrolimus · ANCOVA · p = 0.001 (Alpha was unadjusted.) · Difference in adjusted means: 0.42ANCOVA with treatment as a factor and baseline as a covariate.
  • Sirolimus vs Tacrolimus · ANCOVA · p = <0.001 (Alpha was unadjusted.) · Difference in adjusted means: 0.65ANCOVA with treatment as a factor and baseline as a covariate.
  • Sirolimus vs Tacrolimus · ANCOVA · p = 0.028 (Alpha was unadjusted.) · Difference in adjusted means: 0.37ANCOVA with treatment as a factor and baseline as a covariate.
SecondaryPercentage of Participants Requiring Anti-Hypertensive Medication, Diabetes Agents, Lipid-Lowering Agents, or Erythropoiesis Stimuating Agents (ESAs)
Time frame:
Baseline, Months 12 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Requiring Anti-Hypertensive Medication, Diabetes Agents, Lipid-Lowering Agents, or Erythropoiesis Stimuating Agents (ESAs)
percentage of participantsSirolimusTacrolimus
Baseline, Anti-hypertensives95.492.7
Month 12, Anti-hypertensives75.669.9
Month 24, Anti-hypertensives61.865.9
Baseline, Diabetes agents (insulin)46.647.2
Month 12, Diabetes agents (insulin)26.026.0
Month 24, Diabetes agents (insulin)18.325.2
Baseline, Diabetes agents (non-insulin)14.517.9
Month 12, Diabetes agents (non-insulin)10.713.8
Month 24, Diabetes agents (non-insulin)9.213.0
Baseline, Lipid-lowering agents46.660.2
Month 12, Lipid-lowering agents55.754.5
Month 24, Lipid-lowering agents47.349.6
Baseline, ESAs50.443.1
Month 12, ESAs7.62.4
Month 24, ESAs3.82.4
Statistical analysis
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.429 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.326 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.517 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 1.000 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 1.000 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.223 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.498 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.566 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.423 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.033 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.900 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.802 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.260 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.086 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.723 (Alpha was unadjusted.)
SecondarySpot and 24 Hour Urine Protein to Creatinine Ratio (UPr/Cr)

Baseline was defined as the last nonmissing assessment before or on the date of the first dose of test article.

Time frame:
Baseline and Months 12 and 24
Reported as:
Mean · UPr/Cr
Spot and 24 Hour Urine Protein to Creatinine Ratio (UPr/Cr)
UPr/CrSirolimusTacrolimus
Baseline (n=127,120)0.180 ± 0.14130.195 ± 0.1477
Month 12 (n=112,108)0.353 ± 0.36770.208 ± 0.2234
Month 24 (n=102,106)0.510 ± 0.78870.300 ± 0.6154
Statistical analysis
  • Sirolimus vs Tacrolimus · ANCOVA · p = <0.001 (Alpha was unadjusted.) · Treatment ratio: 1.71 · 95% CI 1.38 to 2.11ANCOVA model with change in the logarithmic Upr/Cr as dependent variable, treatment and logarithmic pre-randomization value as covariate.
  • Sirolimus vs Tacrolimus · ANCOVA · p = <0.001 (Alpha was unadjusted.) · Treatment ratio: 1.77 · 95% CI 1.39 to 2.26ANCOVA model with change in the logarithmic Upr/Cr as dependent variable, treatment and logarithmic pre-randomization value as covariate.
SecondaryPercentage of Participants With Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor Block (ARB) Use

Included ACEI or ARB use prior to randomization, during the on-therapy period (up to 19 to 21 months post randomization) and the off-therapy period (up to 24 months post-transplantation).

Time frame:
Pre-randomization, On-Therapy Period (up to 21 months post-randomization), and Off-Therapy Period (up to 24 months post-transplantation)
Reported as:
Number · percentage of participants
Percentage of Participants With Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor Block (ARB) Use
percentage of participantsSirolimusTacrolimus
Pre-randomization46.646.3
On-Therapy Period43.529.3
Off-Therapy Period32.118.7
Statistical analysis
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 1.000 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.020 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.021 (Alpha was unadjusted.)
SecondaryPercentage of Participants With Stomatitis

Includes adverse events based on categorization by the investigator as stomatitis, regardless of the event preferred term in Medical Dictionary for Regulatory Activities (MedDRA)

Time frame:
From randomization up to 24 months after transplantation (On-Therapy)
Reported as:
Number · percentage of participants
Percentage of Participants With Stomatitis
percentage of participantsSirolimusTacrolimus
Percentage of Participants With Stomatitis28.21.6
Statistical analysis
  • Sirolimus vs Tacrolimus · Fisher Exact · p = <0.001 (Alpha is unadjusted.)
SecondaryPercentage of Participants Requiring Treatment for Stomatitis by Treatment Type

Included treatments (analgesics, dental paste, topical antifungal, topical steroids, or other) prior to randomization, during the on-therapy period (up to 19 to 21 months post-randomization) and the off-therapy period (up to 24 months post-transplantation).

Time frame:
On-Therapy Period (up to 21 months post-randomization) and Off-Therapy Period (up to 24 months post-transplantation)
Reported as:
Number · percentage of participants
Percentage of Participants Requiring Treatment for Stomatitis by Treatment Type
percentage of participantsSirolimusTacrolimus
On-Therapy Period, any treatment17.62.4
Off-Therapy Period, any treatment3.11.6
On-Therapy, analgesics0.80.0
On-Therapy, dental paste3.80.8
On-Therapy, topical steroids5.30.0
On-Therapy, other10.72.4
Off-Therapy, topical steroids1.50.0
Off-Therapy, other1.51.6
Statistical analysis
  • Sirolimus vs Tacrolimus · Fisher Exact · p = <0.001 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.685 (Alpha was unadjusted.)
SecondaryChange From Pre-Randomization to 12 Months Post-Transplantation in Hemoglobin A1C (Liter Per Liter [L/L])

Ratio of hemoglobin A1c to normal hemoglobin.

Time frame:
Baseline, Month 12
Reported as:
Mean · L/L
Change From Pre-Randomization to 12 Months Post-Transplantation in Hemoglobin A1C (Liter Per Liter [L/L])
L/LSirolimusTacrolimus
Change From Pre-Randomization to 12 Months Post-Transplantation in Hemoglobin A1C (Liter Per Liter [L/L])-0.00 ± 0.000.00 ± 0.00
Statistical analysis
  • Sirolimus vs Tacrolimus · ANCOVA · p = 0.521 (Alpha was unadjusted.) · Difference in adjusted means: -0.00
SecondaryChange From Pre-Randomization to 12 Months Post-Transplantation in Fasting Glucose (mmol/L)
Time frame:
Baseline, Month 12
Reported as:
Mean · mmol
Change From Pre-Randomization to 12 Months Post-Transplantation in Fasting Glucose (mmol/L)
mmolSirolimusTacrolimus
Change From Pre-Randomization to 12 Months Post-Transplantation in Fasting Glucose (mmol/L)-0.50 ± 0.31-0.23 ± 0.20
Statistical analysis
  • Sirolimus vs Tacrolimus · ANCOVA · p = 0.265 (Alpha is unadjusted.) · Difference in adjusted means: -0.28ANCOVA with treatment as a factor and baseline as a covariate.
SecondaryChange From Pre-Randomization to 12 Months Post-Transplantation in Fasting Insulin (Picomoles Per Liter [Pmol/L])
Time frame:
Baseline, Month 12
Reported as:
Mean · pmol/L
Change From Pre-Randomization to 12 Months Post-Transplantation in Fasting Insulin (Picomoles Per Liter [Pmol/L])
pmol/LSirolimusTacrolimus
Change From Pre-Randomization to 12 Months Post-Transplantation in Fasting Insulin (Picomoles Per Liter [Pmol/L])27.25 ± 21.9717.14 ± 11.85
Statistical analysis
  • Sirolimus vs Tacrolimus · ANCOVA · p = 0.672 (Alpha was unadjusted.) · Difference in adjusted means: 10.02ANCOVA with treatment as a factor and baseline as a covariate.
SecondaryChange From Pre-Randomization to 12 Months Post-Transplantation in Weight (Kilograms [kg])
Time frame:
Baseline, Month 12
Reported as:
Mean · kg
Change From Pre-Randomization to 12 Months Post-Transplantation in Weight (Kilograms [kg])
kgSirolimusTacrolimus
Change From Pre-Randomization to 12 Months Post-Transplantation in Weight (Kilograms [kg])1.61 ± 0.512.03 ± 0.44
Statistical analysis
  • Sirolimus vs Tacrolimus · ANCOVA · p = 0.504 (Alpha was unadjusted.) · Difference in adjusted means: -0.45ANCOVA with treatment as a factor and baseline as a covariate.
SecondaryChange From Pre-Randomization to 12 Months Post-Transplantation in Waist Circumference(Centimeters [cm])
Time frame:
Baseline, Month 12
Reported as:
Mean · cm
Change From Pre-Randomization to 12 Months Post-Transplantation in Waist Circumference(Centimeters [cm])
cmSirolimusTacrolimus
Change From Pre-Randomization to 12 Months Post-Transplantation in Waist Circumference(Centimeters [cm])1.13 ± 0.732.21 ± 1.00
Statistical analysis
  • Sirolimus vs Tacrolimus · ANCOVA · p = 0.637 (Alpha was unadjusted.) · Difference in adjusted means: -0.56ANCOVA with treatment as a factor and baseline as a covariate.
SecondaryChange From Pre-Randomization to 12 Months Post-Transplantation in Homeostasis Model Assessment Insulin Resistance (HOMA-IR; Fasting)

The HOMA-IR measures insulin resistance based on fasting glucose and insulin measurements: HOMA-IR = fasting plasma glucose (mmol/L) multiplied by (\*) fasting plasma insulin in microunits per liter (µU/L) divided by (/) 22.5. Participants taking insulin within 12 hours were excluded from the analysis.

Time frame:
Baseline, Month 12
Reported as:
Mean · insulin resistance score
Change From Pre-Randomization to 12 Months Post-Transplantation in Homeostasis Model Assessment Insulin Resistance (HOMA-IR; Fasting)
insulin resistance scoreSirolimusTacrolimus
Change From Pre-Randomization to 12 Months Post-Transplantation in Homeostasis Model Assessment Insulin Resistance (HOMA-IR; Fasting)1.14 ± 1.371.10 ± 0.70
Statistical analysis
  • Sirolimus vs Tacrolimus · ANCOVA · p = 0.955 (Alpha was unadjusted.) · Difference in adjusted means: 0.08ANCOVA with treatment as a factor and baseline as a covariate.
SecondaryChange From Pre-Randomization to 12 Months Post-Transplantation in HOMA-Beta Cell (HOMA-B; Fasting)

The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) as a percentage of a normal reference population. HOMA-B = 20 \* insulin (µU/L) / fasting plasma glucose (mmol/L) minus (-) 3.5 Participants taking insulin within 12 hours were excluded from the analysis.

Time frame:
Baseline, Month 12
Reported as:
Mean · percentage beta cell function
Change From Pre-Randomization to 12 Months Post-Transplantation in HOMA-Beta Cell (HOMA-B; Fasting)
percentage beta cell functionSirolimusTacrolimus
Change From Pre-Randomization to 12 Months Post-Transplantation in HOMA-Beta Cell (HOMA-B; Fasting)230.23 ± 214.6826.05 ± 21.99
Statistical analysis
  • Sirolimus vs Tacrolimus · ANCOVA · p = 0.279 (Alpha was unadjusted.) · Difference in adjusted means: 216.29ANCOVA with treatment as a factor and baseline as a covariate.
SecondaryChange From Pre-Randomization to 12 Months Post-Transplantation in Body Mass Index (BMI; in Kilograms Per Square Meter [kg/m^2])

BMI = Weight (kg)/(Height\*Height) (square meters \[m\^2\]).

Time frame:
Baseline, Month 12
Reported as:
Mean · kg/m^2
Change From Pre-Randomization to 12 Months Post-Transplantation in Body Mass Index (BMI; in Kilograms Per Square Meter [kg/m^2])
kg/m^2SirolimusTacrolimus
Change From Pre-Randomization to 12 Months Post-Transplantation in Body Mass Index (BMI; in Kilograms Per Square Meter [kg/m^2])0.53 ± 0.180.75 ± 0.15
Statistical analysis
  • Sirolimus vs Tacrolimus · ANCOVA · p = 0.337 (Alpha was unadjusted.) · Difference in adjusted means: -0.22
SecondaryPercentage of Participants With New-Onset Diabetes

Participants were considered as having new onset diabetes during the On-therapy period if any of the below events emerged from baseline to Month 24: 1) at least 30 days continuous, or at least 25 days non-stop (without gap) use of any diabetic treatment after randomization; 2) a fasting glucose greater than or equal to (≥)126 milligrams per deciliter (mg/dL) after randomization; or 3) a non-fasting glucose ≥200 mg/dL after randomization, were included in the new-onset diabetes population. Events at Months 12 or 24 occurred from baseline to On-therapy Month 12 and from On-therapy Months 12 to 24, respectively.

Time frame:
From Baseline to On-Therapy Month 12, from Baseline to On-Therapy Month 24, and from On-Therapy Month 12 up to On-Therapy Month 24
Reported as:
Number · percentage of participants
Percentage of Participants With New-Onset Diabetes
percentage of participantsSirolimusTacrolimus
New onset (n=82,72)18.35.6
New onset at 1 year (n=82,72)14.62.8
New onset at 2 years (n=70,70)4.32.9
Statistical analysis
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.025 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.012 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 1.000 (Alpha was unadjusted.)
SecondaryPercentage of Participants With New-Onset Diabetes Receiving Treatment for Diabetes (Insulin and Non-Insulin)

Participants were considered as having new onset diabetes during the On-therapy period if any of the below events emerged between baseline and Month 12 or Month 24: 1) at least 30 days continuous, or at least 25 days non-stop (without gap) use of any diabetic treatment after randomization; 2) a fasting glucose ≥126 mg/dL after randomization; or 3) a non-fasting glucose ≥200 mg/dL after randomization.

Time frame:
12 Months and 24 Months
Reported as:
Number · percentage of participants
Percentage of Participants With New-Onset Diabetes Receiving Treatment for Diabetes (Insulin and Non-Insulin)
percentage of participantsSirolimusTacrolimus
Insulin (12-Month)13.30.0
Insulin (24-Month)6.725.0
Non-insulin (12-Month)13.30.0
Non-Insulin (24-Month)13.30.0
Statistical analysis
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 1.000 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 1.000 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.386 (Alpha was unadjusted.)
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 1.000 (Alpha was unadjusted.)
SecondaryPercentage of Participants With Infection

Includes adverse events based on categorization by the investigator as 'infection', regardless of the event preferred term in MedDRA.

Time frame:
From randomization up to 24 months after transplantation (On-Therapy)
Reported as:
Number · percentage of participants
Percentage of Participants With Infection
percentage of participantsSirolimusTacrolimus
Percentage of Participants With Infection61.852.0
Statistical analysis
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.129
SecondaryPercentage of Participants With Cytomegalovirus (CMV) Infection

Includes adverse event terms reported by the investigator to be attributed to the organism 'cytomegalovirus', regardless of the preferred term in MedDRA.

Time frame:
From randomization up to 24 months after transplantation (On-Therapy)
Reported as:
Number · percentage of participants
Percentage of Participants With Cytomegalovirus (CMV) Infection
percentage of participantsSirolimusTacrolimus
Percentage of Participants With Cytomegalovirus (CMV) Infection3.13.3
Statistical analysis
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 1.000
SecondaryPercentage of Participants With Polyomavirus Infection

Includes adverse event terms reported by the investigator to be attributed to the organism 'polyomavirus', regardless of the preferred term in MedDRA.

Time frame:
From randomization up to 24 months after transplantation (On-Therapy)
Reported as:
Number · percentage of participants
Percentage of Participants With Polyomavirus Infection
percentage of participantsSirolimusTacrolimus
Percentage of Participants With Polyomavirus Infection3.87.3
Statistical analysis
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.276
SecondaryPercentage of Participants With Malignancy

Includes any adverse events based on categorization by the investigator as 'malignancy', regardless of the event preferred term in MedDRA.

Time frame:
From randomization up to 24 months after transplantation (On-Therapy)
Reported as:
Number · percentage of participants
Percentage of Participants With Malignancy
percentage of participantsSirolimusTacrolimus
Percentage of Participants With Malignancy3.17.3
Statistical analysis
  • Sirolimus vs Tacrolimus · Fisher Exact · p = 0.158

Adverse events

Collected over From randomization up to 24 months after transplantation (plus [+]4 weeks) for adverse events (AEs) and serious AEs (SAEs).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sirolimus—50/131 (38.2%)116/131 (88.5%)
Tacrolimus—38/123 (30.9%)88/123 (71.5%)
Most frequent serious events
Showing 10 of 100
Most frequent serious events
EventSirolimusTacrolimus
Transplant rejectionImmune system disorders11/1311/123
PneumoniaInfections and infestations6/1313/123
Urinary tract infectionInfections and infestations5/1312/123
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1314/123
PyrexiaGeneral disorders4/1311/123
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1313/123
Kidney transplant rejectionImmune system disorders3/1311/123
Renal artery stenosisRenal and urinary disorders3/1310/123
Hyperparathyroidism tertiaryEndocrine disorders0/1312/123
DiarrhoeaGastrointestinal disorders1/1312/123
Most frequent other events
Showing 10 of 28
Most frequent other events
EventSirolimusTacrolimus
Oedema peripheralGeneral disorders25/1319/123
DiarrhoeaGastrointestinal disorders22/13112/123
Upper respiratory tract infectionInfections and infestations22/13113/123
ProteinuriaRenal and urinary disorders19/1312/123
AcneSkin and subcutaneous tissue disorders19/1311/123
Mouth ulcerationGastrointestinal disorders16/1310/123
HeadacheNervous system disorders16/1317/123
DyslipidemiaMetabolism and nutrition disorders15/1313/123
Urinary tract infectionInfections and infestations14/1318/123
HyperlipidaemiaMetabolism and nutrition disorders14/1314/123

Baseline characteristics

Safety Population: all randomized participants who received at least one dose of the assigned therapy after randomization.

Age, Continuous
Age, Continuous(years)SirolimusTacrolimusTotal
Mean50.7 ± 13.0352.4 ± 12.0551.5 ± 12.57
Sex: Female, Male
Sex: Female, Male(Participants)SirolimusTacrolimusTotal
Female424688
Male8977166
08

Study locations

44 sites
  • Pfizer Investigational Site
    La Jolla, California 92037, United States
  • Pfizer Investigational Site
    San Francisco, California 94115, United States
  • Pfizer Investigational Site
    Aurora, Colorado 80045, United States
  • Pfizer Investigational Site
    Denver, Colorado 80230, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30309, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60611, United States
  • Pfizer Investigational Site
    Lexington, Kentucky 40536, United States
  • Pfizer Investigational Site
    Portland, Maine 04102, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02215, United States
  • Pfizer Investigational Site
    Detroit, Michigan 48202, United States
  • Pfizer Investigational Site
    Detroit, Michigan 48236, United States
  • Pfizer Investigational Site
    New York, New York 10032, United States
  • Pfizer Investigational Site
    Rochester, New York 14642, United States
  • Pfizer Investigational Site
    Chapel Hill, North Carolina 27599 7155, United States
  • Pfizer Investigational Site
    Durham, North Carolina 27705, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45267-0589, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45267-0595, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44106, United States
  • Pfizer Investigational Site
    Portland, Oregon 97239, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • Pfizer Investigational Site
    Charleston, South Carolina 29425, United States
  • Pfizer Investigational Site
    Houston, Texas 77030, United States
  • Pfizer Investigational Site
    Charlottesville, Virginia 22901, United States
  • Pfizer Investigational Site
    Charlottesville, Virginia 22908, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23298, United States
  • Pfizer Investigational Site
    Ciudad de Buenos Aires, Buenos Aires C1425APQ, Argentina
  • Pfizer Investigational Site
    Randwick, New South Wales 2031, Australia
  • Pfizer Investigational Site
    Adelaide, South Australia 5000, Australia
  • Pfizer Investigational Site
    Nedlands, Western Australia 6009, Australia
  • Pfizer Investigational Site
    Porto Alegre, RS 90035-074, Brazil
  • Pfizer Investigational Site
    Bela Vista, Sao Paulo 01323-030, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 01323-000, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 01323-001, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 04038-002, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 04039-033, Brazil
  • Pfizer Investigational Site
    Berlin, 10117, Germany
  • Pfizer Investigational Site
    Milano, 20132, Italy
  • Pfizer Investigational Site
    Milano, 20162, Italy
  • Pfizer Investigational Site
    Barcelona, 08036, Spain
  • Pfizer Investigational Site
    Barcelona, 08907, Spain
  • Pfizer Investigational Site
    Madrid, 28040, Spain
  • Pfizer Investigational Site
    Madrid, 28041, Spain
  • Pfizer Investigational Site
    Santander, 39008, Spain
  • Pfizer Investigational Site
    Valencia, 46026, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2009
First posted
May 8, 2009
Start
Jun 2009
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results first posted
Sep 18, 2014
Last update
Sep 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00895583
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 8, 2009
Start date
Jun 2009
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
Sep 18, 2014
Last update
Sep 18, 2014

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion